Elicio Therapeutics (ELTX) Common Equity (2020 - 2026)

Elicio Therapeutics has reported Common Equity for 7 years, with the latest figure at -$1.4 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 116.14% year-over-year to -$1.4 million; the trailing twelve-month figure through Mar 2026 stood at -$1.4 million (down 116.14% YoY), and the FY2025 full-year result was $1.6 million, up 114.46% from the prior year.
• Common Equity for Q1 2026 stood at -$1.4 million, down from $1.6 million in the prior quarter.
• The five-year high for Common Equity was $23.6 million in Q2 2023, with the low at -$109.9 million in Q1 2023.
• Historically, Common Equity has averaged -$26.0 million across 5 years, with a median of -$1.4 million in 2026.
• Annual changes were most pronounced in 2022 — Common Equity slumped 248.34% — and 2025, when it surged 211.02%.
• Elicio Therapeutics' Common Equity stood at -$102.1 million in 2022, then jumped by 111.13% to $11.4 million in 2023, then plunged by 199.46% to -$11.3 million in 2024, then soared by 114.46% to $1.6 million in 2025, then plunged by 187.84% to -$1.4 million in 2026.
• The last three Common Equity figures came in at -$1.4 million (Q1 2026), $1.6 million (Q4 2025), and $3.8 million (Q3 2025), per Business Quant data.